features: Huntington’s Disease

Relaunching the GENERATION HD trial: how will tominersen fare with younger, milder Huntington’s disease patients?

Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…

Read More

AMT-130: the first gene therapy on the horizon for Huntington’s disease?

The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…

Read More

A slipped-CAG DNA-binding molecule reverses Huntington’s disease repeat CAG mutation

Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disease caused by a CAG trinucleotide repeat expansion in the huntingtin…

Read More
The content of VJNeurology is intended for healthcare professionals